Project Grant R21CA286376
Award Date
8/1/24
Completion Date
9/30/24
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program will support research to investigate how changes in the pre-metastatic niche (PMN) facilitate breast cancer metastasis. The total award amount is $521,240 over the project period from Sep 1, 2024 to Aug 31, 2029. The research aims to identify critical events within the PMN that enable metastatic tumor cell colonization, promote phenotypic heterogeneity, and contribute to drug resistance....
This $619,279 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of Texas Southwestern Medical Center to elucidate the molecular mechanisms underlying metastatic recurrence and immune dysfunction in HER2+ breast cancer. The research employs innovative preclinical models to investigate how disseminated breast cancer cells survive in the brain microenvironment and initiate metachronous metastasis. Specifically, the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $445,500.00 to Southern Illinois University School of Medicine to conduct research on the role of Th2 cytokines in progenitor-mediated formation of tumor lymphatics. The research aims to determine the significance of Th2 pathways in myeloid-derived lymphatic endothelial cell progenitors (M-LECP) and their fusogenic properties in driving tumor lymphangiogenesis. This work may lead to the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover and validate compounds that can block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as well as unravel the role of this engulfment process in cancer metastasis. The $180,632 award, provided from May 1, 2025 to April 30, 2027, will support a multi-faceted research approach at the University of Pittsburgh. Key activities include optimizing a...
This $577,034 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to investigate the relationship between the physical properties of the metastatic microenvironment and the efficacy of the immune system's mechanosurveillance mechanisms in controlling cancer cell growth. The principal investigators, located at the Sloan-Kettering Institute for Cancer Research and collaborating with researchers at Florida State University and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) aims to reveal the comprehensive mechanism of how metastatic breast cancer induces permeability of the blood-brain barrier, thereby facilitating breast cancer brain metastases. The $479,591 award, with a performance period from March 1, 2025 to February 28, 2030, will be performed by the University of Illinois in Chicago. The research will investigate how cancer-derived Fetuin-A protein...
This $230,010 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to unravel the drivers of metastasis in small cell lung cancer (SCLC). The awardee, the University of Chicago, will leverage human pluripotent stem cell-derived pulmonary neuroendocrine cells to model critical stages of SCLC, from tumor initiation to metastatic spread. By examining cell behavior in primary tumors and metastatic sites using advanced...
The National Cancer Institute (NCI) awarded a $678,927 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Medical College of Wisconsin, Inc. to conduct a 5-year study titled "Symptom Monitoring Using Patient-Reported Outcomes to Optimize Medication Use (SYMPTOM)." The project aims to improve adherence to oral endocrine therapy among breast cancer patients by routinely collecting patient-reported symptom data and providing clinical pharmacy-led support to manage symptoms and...
This $2,020,098 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop an innovative X-ray dual-energy cone-beam microCT (DECB microCT) imaging system for intraoperative quantitative analysis of breast lumpectomy specimens. The objective is to enhance the contrast between breast cancer and normal fibroglandular tissue, enabling improved identification of positive surgical margins during breast-conserving surgery. Key project...
The National Cancer Institute awarded a $645,323 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Washington University in St. Louis. The 5-year grant, running from February 1, 2025 to January 31, 2030, supports research into understanding the mechanisms by which acid signaling in bone metastases of breast cancer promotes immune suppression and tumor progression. The research aims to delineate how disruption of acid-induced G protein signaling in tumor cells and...